Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL453953 | 0.95 | ADORA2A (0.57) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL29421357 | 0.95 | ADORA2A (0.57) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL453952 | 0.95 | ADORA2A (0.57) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL453954 | 0.95 | ADORA2A (0.57) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL16555098 | 0.89 | TARS1 (0.54) | ADORA2AADORA2B | |
| SCHEMBL29047905 | 0.87 | ADORA2A (0.60) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL29047902 | 0.87 | ADORA2A (0.60) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL2480941 | 0.87 | ADORA2A (0.62) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL28964452 | 0.87 | ADORA2A (0.56) | ADORA2AADORA2BTP53CYP3A4TSHR | |
| SCHEMBL28964455 | 0.87 | ADORA2A (0.56) | ADORA2AADORA2BTP53CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118338907-A | Lipid Nanoparticle (LNP) compositions and methods of using the same | 宾夕法尼亚大学董事会 | 2024-07-12 | — | — | CN | disclosed |
| CN-118302154-A | RNA vaccine against infectious diseases | 赫德特生物公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118284410-A | Dried nanoparticle compositions | 赫德特生物公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118240812-A | Cationic methods and systems for purification of circular nucleic acids | 上海环码生物医药有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118103514-A | Cyclic RNA compositions and methods | 欧纳医疗公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-110381994-B | Nucleoside modified RNA for inducing immune response against Zika virus | 宾夕法尼亚大学理事会 | 2024-05-10 | — | — | CN | disclosed |
| CN-117979994-A | Oligonucleotides and viral untranslated regions (UTRs) for increased expression of target genes and proteins | 天普大学-联邦高等教育系统 | 2024-05-03 | — | — | CN | disclosed |
| CN-117915946-A | P7-containing nucleoside modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus | 宾夕法尼亚大学理事会 | 2024-04-19 | — | — | CN | disclosed |
| CN-117821458-A | CRISPR/CAS related methods and compositions for treating beta-hemoglobinopathies | 爱迪塔斯医药公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117802102-A | CRISPR/CAS related methods and compositions for treating beta-hemoglobinopathies | 爱迪塔斯医药公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117222422-A | Sanopassing polypeptides and their use in the treatment of cancer | 旗舰创业创新五公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-116887812-A | Formulations for aerosol formation and aerosols for delivery of nucleic acids | 埃泽瑞斯公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116802294-A | Therapeutic agent for treating neurodegenerative disease | UCL商业有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116726203-A | Combination of MRNA encoding immunomodulatory polypeptides and uses thereof | 莫得纳特斯公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116529363-A | RNA-guided clearance of herpes simplex virus type I and other related human herpesviruses | 天普大学-联邦高等教育系统 | 2023-08-01 | — | — | CN | disclosed |
| CN-109476718-B | Combination of MRNA encoding immunomodulatory polypeptides and uses thereof | 莫得纳特斯公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-116334142-A | CRISPR/CAS related methods and compositions for improving transplantation | 爱迪塔斯医药公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-108026526-B | CRISPR/CAS related methods and compositions for improving transplantation | 爱迪塔斯医药公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-115244061-A | Reagents and their use for modular enantioselective synthesis of C-P bonds | 百时美施贵宝公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-113286597-A | Precisely engineered invisible messenger RNAs and other polynucleotides | 科纳勒生物公司 | 2021-08-20 | — | — | CN | disclosed |